Aspirin in diabetic retinopathy: A systematic review

Endocrinology and Metabolism Clinics of North America

Volumn 31, Issue 3, 2002, Pages 779-793

  Bergerhoff, Karla ^a   Clar, Christine ^a   Richter, Bernd ^a  

^a Department of Metabolic Diseases and Nutrition   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE;

BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DIABETES MELLITUS; DIABETIC RETINOPATHY; GASTROINTESTINAL HEMORRHAGE; HUMAN; MEDLINE; META ANALYSIS; MICROANEURYSM; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DIABETIC RETINOPATHY; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036713068     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00017-8     Document Type: Review

References (24)

1. The treatment of diabetic retinopathy: A view for the internist
2. Epidemiology of blindness and eye disease
3. Incidence of blindness in relation to diabetes: A population-based study
4. Clinical study of ticlopidine in diabetic retinopathy
5. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years
6. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early treatment diabetic retinopathy study report #18
7. Prospective Diabetes Study UK (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
9. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes
10. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy
11. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
12. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
13. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial
14. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optinal Treatment (HOT) randomised trial
15. Does increased platelet aggregation have a prognostic value in the deterioration of background diabetic retinopathy?
16. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1
17. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 8
18. Retinal blood flow increases following short-term aspirin usage in type I diabetics with no or minimal retinopathy
19. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: A multicenter randomized controlled clinical trial
20. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus: ETDRS report number 20
21. Early treatment diabetic retinopathy study design and baseline patient characteristics: ETDRS report number 7
22. Aspirin effects on mortality and morbidity in patients with diabetes mellitus
23. Aspirin effects on the development of cataracts in patients with diabetes mellitus: ETDRS report number 16
24. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients